Abstract: Maximizing the Advantages of US and EU Orphan Drug Designation Incentives

 

Abstract: Maximizing the Advantages of US and EU Orphan Drug Designation Incentives

• To summarize regulations regarding orphan drug designation in the US and EU • To discuss and demonstrate how drug developers can take advantage of the regulators’ incentives to optimize their investment in orphan drug development

• To summarize regulations regarding orphan drug designation in the US and EU • To discuss and demonstrate how drug developers can take advantage of the regulators’ incentives to optimize their investment in orphan drug development